/BJDX
BJDX Stock - Bluejay Diagnostics, Inc.
Healthcare|Medical - DevicesNASDAQ
$0.80-12.64%
$0.12 (-12.64%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.5
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.95
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.88
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BJDX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.79 – $0.81
TARGET (TP)$0.92
STOP LOSS$0.74
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.61
52W High$10.20
52W Low$0.78
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $249,040 | N/A | N/A |
| Gross Profit | N/A | N/A | $48,911 | $-145,719 | $-157,039 |
| Gross Margin | N/A | N/A | 19.6% | N/A | N/A |
| Operating Income | $-7,169,616 | $-10,311,217 | $-9,317,776 | $-3,230,163 | $-1,196,391 |
| Net Income | $-7,717,794 | $-9,953,888 | $-9,296,948 | $-3,729,686 | $-1,125,716 |
| Net Margin | N/A | N/A | -3733.1% | N/A | N/A |
| EPS | $-42.08 | $-72.62 | $-73.22 | $-29.67 | $-14.19 |
Company Overview
Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
BJDXBeat Rate
17%
Last 12 quarters
Avg Surprise
-147.7%
EPS vs Estimate
Beats / Misses
2/10
Last 12 quarters
Latest EPS
$-1.01
Q4 2025
EPS Surprise History
Q1 24
-161.8%
$-712.00vs$-272.00
Q2 24
-37.5%
$-396.00vs$-288.00
Q3 24
-611.1%
$-256.00vs$-36.00
Q4 24
+77.8%
$-8.00vs$-36.00
Q1 25
-212.1%
$-112.37vs$-36.00
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 7, 2025 | — | $-1.01 | — | — |
Q3 2025 | Aug 7, 2025 | — | $-1.41 | — | — |
Q2 2025 | May 13, 2025 | — | $-3.37 | — | — |
Q1 2025 | Mar 31, 2025 | $-36.00 | $-112.37 | -212.1% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-36.00 | $-8.00 | +77.8% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-36.00 | $-256.00 | -611.1% | ✗ MISS |
Q2 2024 | May 15, 2024 | $-288.00 | $-396.00 | -37.5% | ✗ MISS |
Q1 2024 | Mar 28, 2024 | $-272.00 | $-712.00 | -161.8% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-328.00 | $-832.00 | -153.7% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-600.00 | $-1100.00 | -83.3% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-480.00 | $-960.00 | -100.0% | ✗ MISS |
Q1 2023 | Mar 20, 2023 | $320.00 | $-960.00 | -400.0% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $-640.00 | $-1120.00 | -75.0% | ✗ MISS |
Q3 2022 | Jul 26, 2022 | $-640.00 | $-800.00 | -25.0% | ✗ MISS |
Q2 2022 | Apr 20, 2022 | $-880.00 | $-800.00 | +9.1% | ✓ BEAT |
Q1 2022 | Mar 10, 2022 | — | $-720.00 | — | — |
Q4 2021 | Dec 16, 2021 | — | $-9.79 | — | — |
Q4 2021 | Nov 12, 2021 | — | $-6.09 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-2.47 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-6.86 | — | — |
Latest News
Bluejay Diagnostics Pushes Forward with 20-Minute Sepsis Test, Reports $3M in Cash, But Needs $20M to Reach FDA Goal
📉 NegativeBenzinga•Nov 10, 2025, 12:52 PM•Also:
Bluejay Diagnostics Shares Resume Trade
➖ NeutralBenzinga•Oct 9, 2025, 07:31 PM
Bluejay Diagnostics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 86.10%
📈 PositiveBenzinga•Oct 9, 2025, 07:21 PM
Bluejay Diagnostics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 56.15%
📈 PositiveBenzinga•Oct 9, 2025, 07:17 PM
Bluejay Diagnostics Announces $4.5M Private Placement Selling 2.25M Shares And Series F Warrants To Purchase Up To 4.5M Shares Of Common Stock At A Purchase Price Of $2.00
➖ NeutralBenzinga•Oct 9, 2025, 07:16 PM•Also:
Bluejay Diagnostics shares are trading higher after the company announced it entered into an Agreement to Amend the Master Service Agreement and the Master Supply Agreement with SanyoSeiko.
📈 PositiveBenzinga•Oct 9, 2025, 12:59 PM
Market-Moving News for October 9th
➖ NeutralBenzinga•Oct 9, 2025, 11:16 AM•Also: ,
Bluejay Diagnostics Expanded Sanyoseiko Role In Commercializing Symphony Near-Patient Testing Platform For IL-6 Sepsis Biomarker Results Through Amended Service And Supply Agreements
📈 PositiveBenzinga•Oct 9, 2025, 10:10 AM
Bluejay Diagnostics Appoints Donald R. Chase As Chairperson Of Bluejay Board
➖ NeutralBenzinga•Aug 15, 2025, 09:40 PM
Frequently Asked Questions about BJDX
What is BJDX's current stock price?
Bluejay Diagnostics, Inc. (BJDX) is currently trading at $0.80 per share. The stock has moved -12.64% today.
What is the analyst price target for BJDX?
No analyst price targets are currently available for this stock.
What sector is Bluejay Diagnostics, Inc. in?
Bluejay Diagnostics, Inc. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is BJDX's market cap?
Bluejay Diagnostics, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does BJDX pay dividends?
No, Bluejay Diagnostics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBCTXZ
BriaCell Therapeutics Corp. Warrant
$0.39
Mkt Cap: $0.0B
ELAB
PMGC Holdings Inc.
$2.26
Mkt Cap: $0.0B
MLEC
Moolec Science S.A.
$0.33
Mkt Cap: $0.0B
MSPR
MSP Recovery, Inc.
$0.20
Mkt Cap: $0.0B
NKGN
NKGen Biotech, Inc. Common Stock
$0.05
Mkt Cap: $0.0B
TIVC
Tivic Health Systems, Inc.
$1.74
Mkt Cap: $0.0B
UPC
Universe Pharmaceuticals Inc.
$3.73
Mkt Cap: $0.0B
VTAK
Catheter Precision, Inc.
$1.98
Mkt Cap: $0.0B
WGS
GeneDx Holdings Corp.
$140.44
Mkt Cap: $4.1B
WINT
Windtree Therapeutics, Inc.
$0.04
Mkt Cap: $0.0B
Explore stocks similar to BJDX for comparison